Why the study?
Does catheter ablation improve clinical outcomes compared to medical therapy in patients with atrial fibrillation and heart failure with reduced ejection fraction?
Does catheter ablation improve clinical outcomes compared to medical therapy in patients with atrial fibrillation and heart failure with reduced ejection fraction?
Catheter ablation is emerging as a superior strategy compared to medical therapy for managing atrial fibrillation in patients with HFrEF, offering improvements in left ventricular function, symptoms, and potentially survival.
Answers are grounded in this paper and cite their sources.
Supports ablation preference in AF-HFrEF; leaves open confirmatory RCTs for survival benefit.
Heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation (AF) are the two epidemics and present concomitantly with worse prognoses. According to the guidelines, rate control and rhythm control are the comparable selection, because rhythm control with Antiarrhythmic drugs (AADs) is not superior to rate control and anticoagulation. The CASTLE-AF trial argues the current guidelines endorse catheter ablation as first-line therapy for the treatment of AF in patients with HFrEF regardless of AF type. Late gadolinium enhancement magnetic resonance imaging scans (LGE-CMR) assessment has also been promising to regard predicting immediate efficacy and late outcomes after ablation. Selecting adequate AF patients with HFrEF, catheter ablation can result in significant improvement in LVEF, quality of life and functional status, with a survival benefit.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: